医学
比伐卢定
部分凝血活酶时间
体外膜肺氧合
血栓弹性成像
麻醉
凝血酶原时间
人口
凝血时间激活
心脏病学
内科学
体外循环
凝结
环境卫生
心肌梗塞
经皮冠状动脉介入治疗
作者
Mitchell S. Buckley,Grace Benanti,Jordan Meckel,Luwam A. Tekle,Brian W. Gilbert,D.A. Puebla Neira,Dakota A. McNierney,Grace Korkames,Melanie Yerondopoulos,Andrew Park,Jennifer O’Hea,Robert MacLaren
摘要
Abstract Study Objective Thromboelastography (TEG) offers a more dynamic assessment of hemostasis over activated partial thromboplastin time (aPTT). However, the clinical utility of TEG in monitoring bivalirudin during extracorporeal membrane oxygenation (ECMO) remains unknown. The purpose of this study was to evaluate the correlation between aPTT and TEG in adult ECMO patients anticoagulated with bivalirudin. Design Multicenter, retrospective, cohort study conducted over a 2‐year period. Setting Two academic university medical centers (Banner University Medical Center) in Phoenix and Tucson, AZ. Patients Adult patients requiring ECMO and bivalirudin therapy with ≥1 corresponding standard TEG and aPTT plasma samples drawn ≤4 h of each other were included. The primary endpoint was to determine the correlation coefficient between the standard TEG reaction (R) time and bivalirudin aPTT serum concentrations. Measurements and Main Results A total of 104 patients consisting of 848 concurrent laboratory assessments of R time and aPTT were included. A moderate correlation between TEG R time and aPTT was demonstrated in the study population ( r = 0.41; p < 0.001). Overall, 502 (59.2%) concurrent assessments of TEG R time and aPTT values showed agreement on whether they were sub‐, supra‐, or therapeutic according to the institution's classification for bivalirudin. The 42.2% ( n = 271/642) discordant TEG R times among “therapeutic” aPTT were almost equally distributed between subtherapeutic and supratherapeutic categories. Conclusions Moderate correlation was found between TEG R time and aPTT associated with bivalirudin during ECMO in critically ill adults. Further research is warranted to address the optimal test to guide clinical decision‐making for anticoagulation dosing in ECMO patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI